- Correction
- Open access
- Published:
Correction: Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clinical trials
Journal of Nanobiotechnology volume 22, Article number: 16 (2024)
The Original Article was published on 13 December 2023
Correction: Journal of Nanobiotechnology (2023) 21:473
Following publication of the original article [1], the authors reported that the 2nd author was omitted from the author group. Richard B. Dewey III has been added to the author group both in the original article and in this correction article.
In addition, the authors identified an error in affiliation 1. The affiliation was incorrectly given as “Department of Neurology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390, USA”, but should have been “University of Texas Southwestern Medical Center, Department of Neurology, 5323 Harry Hines Blvd., Dallas, TX 75390”. This error is corrected in the affiliations list below and in the original article.
References
Ren J, Dewey RB, Rynders A et al. Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials. J Nanobiotechnol. 2023;21(1):478. https://doi.org/10.1186/s12951-023-02236-z.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1186/s12951-023-02236-z.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Ren, J., Dewey, R.B., Rynders, A. et al. Correction: Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clinical trials. J Nanobiotechnol 22, 16 (2024). https://doi.org/10.1186/s12951-023-02269-4
Published:
DOI: https://doi.org/10.1186/s12951-023-02269-4